blood pump News
-
Puzzle Medical announces partnership with Patent Attorney Scott Talbot from U.S. firm Cooley LLP
Puzzle Medical Devices Inc. is enthusiastic to partner with Patent Attorney C. Scott Talbot from Cooley LLP as it continues to grow its patent portfolio. Cooley LLP is the largest medical technology patent team in the US. Scott has more than two decades of experience in the medical technology industry, including with prosthetic heart valves, heart valve repair, orthopedic surgery, stents, blood ...
-
Procyrion Names AV Edidin, Ph.D., as Senior Vice President of Development and Manufacturing
Procyrion, Inc., a clinical-stage medical device company developing the Aortix™ system, a percutaneous blood pump initially targeted for treating patients with heart failure and worsening kidney function (cardiorenal syndrome), announced the appointment of Av Edidin, Ph.D., as Senior Vice President of Development and Manufacturing. In this role, Edidin will lead and oversee product ...
-
Showcase
ALung Announces Commercial Development of its Breakthrough Next Generation Artificial Lung
PITTSBURGH–(BUSINESS WIRE)– April 4, 2020 – ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, announced the recent initiation of commercial development of its next generation artificial lung, which expands the Company’s focus on highly efficient gas ...
-
Procyrion Raises $30 Million Series D to Support Clinical Trials of Its Aortix™ Percutaneous Blood Pump for Treating Heart Failure Patients
Procyrion, Inc., a clinical-stage medical device company, today announced the completion of a $30 million Series D funding round led by a new investor, Bluebird Ventures. Returning investors include Fannin Partners, Scientific Health Development, the State of Texas, and an undisclosed strategic investor. The company is developing its Aortix™ system, a percutaneous blood pump initially ...
-
CorWave Reports Two Critical Technical Milestones Required to Proceed to the Clinical Phase at the American Society for Artificial Internal Organs Annual Meeting
CorWave announced today that the latest results of its preclinical Left Ventricular Assist Device (LVAD) development program are presented at the 2020 Virtual OnDemand Conference of the American Society for Artificial Organs (ASAIO), in the Top Abstracts session, available on the ASAIO website1. The presentation, entitled “In Silico, In Vitro and In Vivo Evaluation of the CorWave Membrane ...
By CorWave
-
CorWave Presents an Unprecedented Chronic In Vivo Study at the 41st Annual Meeting of the International Society of Heart and Lung Transplantation
CorWave, a French medical device company committed to the fight against heart failure, unveiled an unprecedented study on the performance of its implantable heart pump at the 41st Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT). The company presented the first ever study demonstrating sensorless synchronization of a pericardial pump with the native heart for ...
By CorWave
-
Berlin Heart Received CE Mark and Announces First Implantation of the Latest Cannula Generation to Treat Heart Patients Waiting for a Donor Heart
Berlin, September 2021: Berlin Heart today announces the CE mark and first implantation of an innovative outflow cannula for mechanical circulatory support with the paracorporeal pulsatile EXCOR® ventricular assist device. The EXCOR® Graft Cannula* connects the outflow side of the blood pump to the ascending aorta for left ventricular support or to the pulmonary artery for right ...
-
Cardiac Dimensions Announces $17.5 Million Series C Financing to Accelerate Sales Expansion of the Carillon Mitral Contour System
Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the company has closed a $17.5 million Series C financing. All existing shareholders participated in the round including Aperture Venture Partners, Arboretum Ventures, Hostplus, Life Sciences Partners, Lumira ...
-
Supira Medical, A Shifamed Portfolio Company, Closes $35M in Series B Financing
Company Appoints Seasoned Medtech Executive as President and CEO CAMPBELL, Calif., March 5, 2020 – Supira Medical, formed by Shifamed as part of its medical innovation hub, announced today the closing of $35M in Series B financing. Officially closed on February 25, the financing was led by Cormorant Asset Management with participation from The Capital Partnership (TCP), 415 CAPITAL, AMED ...
-
Supira Medical, A Shifamed Portfolio Company, Closes $30m in an Oversubscribed Series C Financing
Company to Advance its Next Generation Percutaneous Ventricular Assist Device Los Gatos, Calif., February 28, 2022 – Supira Medical, Inc., a Shifamed portfolio company that is focused on developing a next-generation solution for temporary mechanical circulatory support, announced today the closing of $30M in Series C financing. Led by Cormorant Asset Management and The Capital Partnership ...
-
CardioWise™ Receives ISO 13485:2016 Clearance for Design, Development, and Marketing of Software as a Medical Device (SaMD) For the Medical Device Industry
CardioWise, Inc., is pleased to announce that Perry Johnson Registrars, Incorporated has audited the CardioWise Quality Management System (QMS) and determined CardioWise is in conformance with ISO 13485:2016. Perry Johnson Registrars Certificate C2022-02910 was issued July 16, 2022, and represents the first step in the process of obtaining a CE mark and Medical Device Registration for the ...
-
CVRx Announces First Clinical Procedure with a New Ultrasound-Guided Implant Approach, the Latest Advancement in Barostim™ for the Treatment of Heart Failure Symptoms
MINNEAPOLIS, June 10, 2021 - CVRx©. developer of the world's first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF). announced the completion of the first clinical procedure with the company's new lead implantation approach. The novel ultrasound-guided technique is the latest advancement of CVRx's Barostim™ Baroreflex Activation Therapy (BAT™) to ...
By CVRx
-
Ancora Heart Announces Expansion of U.S. Early Feasibility Study
Santa Clara, Calif.– February 3, 2020 – Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of enrollment in its CorCinch HFrEF Early Feasibility Study (EFS), which is evaluating the AccuCinch® Ventricular Repair System in patients with reduced ejection ...
-
BioVentrix Announces Raymond W. Cohen as Chairman of the Board and Newly Appointed Accredited Public Company Directors, Rinda K. Sama and Andrew G. Hinson to its Board of Directors
BioVentrix, Inc., a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), today announced the appointment of Raymond W. Cohen as the Company’s chairman and named Rinda K. Sama and Andrew G. Hinson to its board of directors. Mr. Cohen has over 40 years’ experience leading and guiding a variety of private ...
-
Procyrion’S Aortix Percutaneous Mechanical Circulatory Support Device to be Showcased at Tct 2021 Annual Meeting
Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today the schedule of presentations to be featured at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Orlando, Florida from November 4th to November 6th. The presentations include a spotlight on the company’s first US case treating a ...
-
CVRx Receives MR-Conditional Labeling Approval for its Barostim Heart Failure System
MINNEAPOLIS, MAY 9,2022 - CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), developer of the world's first FDA-approved neuromodulation device to treat the symptoms of heart failure, has received U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR) conditional labeling for its Barostim System. The Barostim System now includes instructions to allow for safe MRI scans of the head and ...
By CVRx
-
BioVentrix Expands Heart Failure Treatment Portfolio with Acquisition of MateraCor, Inc.
BioVentrix, Inc., a privately held medical device company focused on less invasive therapies to treat the left ventricle (LV), known to be the root cause of congestive heart failure (CHF), today announced that it has acquired MateraCor, Inc., a company focused on preventing progression of, and reversing, heart failure through the use of injectable alginate-based hydrogel. “This is an ...
-
Air pollution from road traffic can raise blood pressure
High blood pressure is linked to long-term exposure to traffic-related air pollution, new research suggests. After accounting for lifestyle factors, socioeconomic status and pre-existing health conditions, the researchers found that a rise in traffic emissions of nitrogen dioxide corresponded to a rise in blood pressure of exposed individuals. Long-term exposure to air pollution has previously ...
-
Portable Hydrogen Rich Water Generator Bottle Benefits
Proper hydration is essential to life and promotes better all-round health. Hydrogen water is a practical alternative for those that prefer to avoid drinking local tap water. Plain tap water can include a long list of contaminants, such as heavy metals, chlorine, fluoride and arsenic. Hydrogen water is a great option to stay hydrated and includes a wide range of positive benefits such as ...
-
Fresenius Medical Care expands critical care offering with ExThera Medical’s Seraph 100 adsorber
Fresenius Medical Care, the world’s leading provider of products and services for people with chronic kidney failure, will offer the Seraph 100 Microbind Affinity Blood Filter from ExThera Medical Corporation in several European countries as of now. Both companies have signed a co-marketing and distribution agreement, effective in January 2021 and covering Belgium, Denmark, France, Germany, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you